Induce-1: a phase I open-label study of GSK3359609, an ICOS agonist antibody, administered alone and in combination with pembrolizumab in patients with selected, advanced solid tumors

Eric Angevin; Todd M. Bauer; Catherine E. Ellis; Hui Gan; Rigel Hall; Aaron Hansen; Axel Hoos; Roxanne C. Jewell; Jessica Katz; Juan Martin-Liberal; Michele Maio; Patrick A. Mayes; Jolly Mazumdar; Michael Millward; Danny Rischin; Jan H. Schellens; Sapna Yadavilli; Helen Zhou

doi:10.1158/1538-7445.AM2017-CT039

Induce-1: a phase I open-label study of GSK3359609, an ICOS agonist antibody, administered alone and in combination with pembrolizumab in patients with selected, advanced solid tumors

Eric Angevin, Todd M. Bauer, Catherine E. Ellis, Hui Gan, Rigel Hall, Aaron Hansen, Axel Hoos, Roxanne C. Jewell, Jessica Katz, Juan Martin-Liberal, Michele Maio, Patrick A. Mayes, Jolly Mazumdar, Michael Millward, Danny Rischin, Jan H. Schellens, Sapna Yadavilli, Helen Zhou

Research output: Contribution to journal › Abstract/Meeting Abstract › peer-review

6 Citations (Web of Science)

Original language	English
Number of pages	2
Journal	Cancer Research
Volume	77
DOIs	https://doi.org/10.1158/1538-7445.AM2017-CT039
Publication status	Published - Jul 2017
Externally published	Yes
Event	108th Annual Meeting of the American-Association-for-Cancer-Research - Washington, United States Duration: 1 Apr 2017 → 5 Apr 2017

Access to Document

10.1158/1538-7445.AM2017-CT039

Cite this

Angevin, E., Bauer, T. M., Ellis, C. E., Gan, H., Hall, R., Hansen, A., Hoos, A., Jewell, R. C., Katz, J., Martin-Liberal, J., Maio, M., Mayes, P. A., Mazumdar, J., Millward, M., Rischin, D., Schellens, J. H., Yadavilli, S., & Zhou, H. (2017). Induce-1: a phase I open-label study of GSK3359609, an ICOS agonist antibody, administered alone and in combination with pembrolizumab in patients with selected, advanced solid tumors. Cancer Research, 77. https://doi.org/10.1158/1538-7445.AM2017-CT039

@article{2f0e98cd84a84ba78b301785cc159cc3,

title = "Induce-1: a phase I open-label study of GSK3359609, an ICOS agonist antibody, administered alone and in combination with pembrolizumab in patients with selected, advanced solid tumors",

author = "Eric Angevin and Bauer, {Todd M.} and Ellis, {Catherine E.} and Hui Gan and Rigel Hall and Aaron Hansen and Axel Hoos and Jewell, {Roxanne C.} and Jessica Katz and Juan Martin-Liberal and Michele Maio and Mayes, {Patrick A.} and Jolly Mazumdar and Michael Millward and Danny Rischin and Schellens, {Jan H.} and Sapna Yadavilli and Helen Zhou",

year = "2017",

month = jul,

doi = "10.1158/1538-7445.AM2017-CT039",

language = "English",

volume = "77",

journal = "Cancer Research",

issn = "0008-5472",

publisher = "American Association for Cancer Research (AACR)",

note = "108th Annual Meeting of the American-Association-for-Cancer-Research, AACR ; Conference date: 01-04-2017 Through 05-04-2017",

}

Angevin, E, Bauer, TM, Ellis, CE, Gan, H, Hall, R, Hansen, A, Hoos, A, Jewell, RC, Katz, J, Martin-Liberal, J, Maio, M, Mayes, PA, Mazumdar, J, Millward, M, Rischin, D, Schellens, JH, Yadavilli, S & Zhou, H 2017, 'Induce-1: a phase I open-label study of GSK3359609, an ICOS agonist antibody, administered alone and in combination with pembrolizumab in patients with selected, advanced solid tumors', Cancer Research, vol. 77. https://doi.org/10.1158/1538-7445.AM2017-CT039

TY - JOUR

T1 - Induce-1

T2 - 108th Annual Meeting of the American-Association-for-Cancer-Research

AU - Angevin, Eric

AU - Bauer, Todd M.

AU - Ellis, Catherine E.

AU - Gan, Hui

AU - Hall, Rigel

AU - Hansen, Aaron

AU - Hoos, Axel

AU - Jewell, Roxanne C.

AU - Katz, Jessica

AU - Martin-Liberal, Juan

AU - Maio, Michele

AU - Mayes, Patrick A.

AU - Mazumdar, Jolly

AU - Millward, Michael

AU - Rischin, Danny

AU - Schellens, Jan H.

AU - Yadavilli, Sapna

AU - Zhou, Helen

PY - 2017/7

Y1 - 2017/7

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=uwapure5-25&SrcAuth=WosAPI&KeyUT=WOS:000442496700033&DestLinkType=FullRecord&DestApp=WOS

U2 - 10.1158/1538-7445.AM2017-CT039

DO - 10.1158/1538-7445.AM2017-CT039

M3 - Abstract/Meeting Abstract

SN - 0008-5472

VL - 77

JO - Cancer Research

JF - Cancer Research

Y2 - 1 April 2017 through 5 April 2017

ER -

Induce-1: a phase I open-label study of GSK3359609, an ICOS agonist antibody, administered alone and in combination with pembrolizumab in patients with selected, advanced solid tumors

Access to Document

Other files and links

Cite this